Glenmark Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has informed exchanges about a Board meeting scheduled for May 29, 2026. The meeting will consider and approve the Standalone and Consolidated Audited Financial Results for Q4 and the financial year ended March 31, 2026. The Board will also consider recommending a dividend on equity shares for FY 2025-26. Additionally, the company has closed the trading window for insiders from March 31, 2026 to May 31, 2026, which is standard practice under SEBI regulations ahead of financial results disclosure.
The trading window closure is routine compliance and prevents insider trading before results. Investors can expect Q4 and full-year results along with a potential dividend announcement by end of May 2026. No immediate impact on stock movement, but the dividend consideration is a positive signal for shareholders.